Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

Lucia Del Mastro, Marco Venturini, Rita Lionetto, Ornella Garrone, Giovanni Melioli, Wanda Pasquetti, Mario Roberto Sertoli, Gianfilippo Bertelli, Giuseppe Canavese, Massimo Costantini, Riccardo Rosso

Research output: Contribution to journalArticle

Abstract

Purpose: Although erythropoietin (EPO) is known to be useful in treating chemotherapy-induced anemia, few data are available on its potential preventive role. The aim of this study was to evaluate the ability of EPO in preventing the development of clinically significant anemia in patients treated with chemotherapy. Patients and Methods: Sixty-two early- stage breast cancer patients undergoing accelerated adjuvant chemotherapy were randomized to receive EPO 150 U/kg three times a week or no additional treatment. Chemotherapy consisted of six cycles of cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2, and fluorauraci1 600 mg/m2 (CEF) intravenously on day 1, every 2 weeks with the support of granulocyte colony-stimulating factor (G-CSF), 5 μg/kg subcutaneously from day 4 to day 11. Results: Throughout the six cycles of chemotherapy, EPO-treated patients maintained stable values of hemoglobin, whereas control patients developed a progressive anemia. At the end of chemotherapy, the mean (± SD) hemoglobin decrease in the control group was 3.05 g/dL (± 1.0; 95% confidence interval [CI], 2.6 to 3.5), whereas in the EPO group it was 0.8 (± 1.4; 95% CI, 0.3 to 1.4). Clinically significant anemia (hemoglobin ≤ 10 g/dL) occurred in 16 patients (52%; 95% CI, 33 to 69) in the control arm and in no patient (0%; 95% CI, 0 to 14) in the EPO arm (P = .00001). Conclusion: EPO prevents anemia in patients undergoing chemotherapy. Further trials are required to identify subsets of patients in which the preventive use of this drug could be cost-effective.

Original languageEnglish
Pages (from-to)2715-2721
Number of pages7
JournalJournal of Clinical Oncology
Volume15
Issue number7
Publication statusPublished - Jul 1997

Fingerprint

Erythropoietin
Anemia
Drug Therapy
Confidence Intervals
Hemoglobins
Epirubicin
Granulocyte Colony-Stimulating Factor
Adjuvant Chemotherapy
Cyclophosphamide
Breast Neoplasms
Costs and Cost Analysis
Control Groups
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Del Mastro, L., Venturini, M., Lionetto, R., Garrone, O., Melioli, G., Pasquetti, W., ... Rosso, R. (1997). Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. Journal of Clinical Oncology, 15(7), 2715-2721.

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. / Del Mastro, Lucia; Venturini, Marco; Lionetto, Rita; Garrone, Ornella; Melioli, Giovanni; Pasquetti, Wanda; Sertoli, Mario Roberto; Bertelli, Gianfilippo; Canavese, Giuseppe; Costantini, Massimo; Rosso, Riccardo.

In: Journal of Clinical Oncology, Vol. 15, No. 7, 07.1997, p. 2715-2721.

Research output: Contribution to journalArticle

Del Mastro, L, Venturini, M, Lionetto, R, Garrone, O, Melioli, G, Pasquetti, W, Sertoli, MR, Bertelli, G, Canavese, G, Costantini, M & Rosso, R 1997, 'Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia', Journal of Clinical Oncology, vol. 15, no. 7, pp. 2715-2721.
Del Mastro, Lucia ; Venturini, Marco ; Lionetto, Rita ; Garrone, Ornella ; Melioli, Giovanni ; Pasquetti, Wanda ; Sertoli, Mario Roberto ; Bertelli, Gianfilippo ; Canavese, Giuseppe ; Costantini, Massimo ; Rosso, Riccardo. / Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 7. pp. 2715-2721.
@article{18e3b6dacebe445c946e019cec8474d7,
title = "Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia",
abstract = "Purpose: Although erythropoietin (EPO) is known to be useful in treating chemotherapy-induced anemia, few data are available on its potential preventive role. The aim of this study was to evaluate the ability of EPO in preventing the development of clinically significant anemia in patients treated with chemotherapy. Patients and Methods: Sixty-two early- stage breast cancer patients undergoing accelerated adjuvant chemotherapy were randomized to receive EPO 150 U/kg three times a week or no additional treatment. Chemotherapy consisted of six cycles of cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2, and fluorauraci1 600 mg/m2 (CEF) intravenously on day 1, every 2 weeks with the support of granulocyte colony-stimulating factor (G-CSF), 5 μg/kg subcutaneously from day 4 to day 11. Results: Throughout the six cycles of chemotherapy, EPO-treated patients maintained stable values of hemoglobin, whereas control patients developed a progressive anemia. At the end of chemotherapy, the mean (± SD) hemoglobin decrease in the control group was 3.05 g/dL (± 1.0; 95{\%} confidence interval [CI], 2.6 to 3.5), whereas in the EPO group it was 0.8 (± 1.4; 95{\%} CI, 0.3 to 1.4). Clinically significant anemia (hemoglobin ≤ 10 g/dL) occurred in 16 patients (52{\%}; 95{\%} CI, 33 to 69) in the control arm and in no patient (0{\%}; 95{\%} CI, 0 to 14) in the EPO arm (P = .00001). Conclusion: EPO prevents anemia in patients undergoing chemotherapy. Further trials are required to identify subsets of patients in which the preventive use of this drug could be cost-effective.",
author = "{Del Mastro}, Lucia and Marco Venturini and Rita Lionetto and Ornella Garrone and Giovanni Melioli and Wanda Pasquetti and Sertoli, {Mario Roberto} and Gianfilippo Bertelli and Giuseppe Canavese and Massimo Costantini and Riccardo Rosso",
year = "1997",
month = "7",
language = "English",
volume = "15",
pages = "2715--2721",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

AU - Del Mastro, Lucia

AU - Venturini, Marco

AU - Lionetto, Rita

AU - Garrone, Ornella

AU - Melioli, Giovanni

AU - Pasquetti, Wanda

AU - Sertoli, Mario Roberto

AU - Bertelli, Gianfilippo

AU - Canavese, Giuseppe

AU - Costantini, Massimo

AU - Rosso, Riccardo

PY - 1997/7

Y1 - 1997/7

N2 - Purpose: Although erythropoietin (EPO) is known to be useful in treating chemotherapy-induced anemia, few data are available on its potential preventive role. The aim of this study was to evaluate the ability of EPO in preventing the development of clinically significant anemia in patients treated with chemotherapy. Patients and Methods: Sixty-two early- stage breast cancer patients undergoing accelerated adjuvant chemotherapy were randomized to receive EPO 150 U/kg three times a week or no additional treatment. Chemotherapy consisted of six cycles of cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2, and fluorauraci1 600 mg/m2 (CEF) intravenously on day 1, every 2 weeks with the support of granulocyte colony-stimulating factor (G-CSF), 5 μg/kg subcutaneously from day 4 to day 11. Results: Throughout the six cycles of chemotherapy, EPO-treated patients maintained stable values of hemoglobin, whereas control patients developed a progressive anemia. At the end of chemotherapy, the mean (± SD) hemoglobin decrease in the control group was 3.05 g/dL (± 1.0; 95% confidence interval [CI], 2.6 to 3.5), whereas in the EPO group it was 0.8 (± 1.4; 95% CI, 0.3 to 1.4). Clinically significant anemia (hemoglobin ≤ 10 g/dL) occurred in 16 patients (52%; 95% CI, 33 to 69) in the control arm and in no patient (0%; 95% CI, 0 to 14) in the EPO arm (P = .00001). Conclusion: EPO prevents anemia in patients undergoing chemotherapy. Further trials are required to identify subsets of patients in which the preventive use of this drug could be cost-effective.

AB - Purpose: Although erythropoietin (EPO) is known to be useful in treating chemotherapy-induced anemia, few data are available on its potential preventive role. The aim of this study was to evaluate the ability of EPO in preventing the development of clinically significant anemia in patients treated with chemotherapy. Patients and Methods: Sixty-two early- stage breast cancer patients undergoing accelerated adjuvant chemotherapy were randomized to receive EPO 150 U/kg three times a week or no additional treatment. Chemotherapy consisted of six cycles of cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2, and fluorauraci1 600 mg/m2 (CEF) intravenously on day 1, every 2 weeks with the support of granulocyte colony-stimulating factor (G-CSF), 5 μg/kg subcutaneously from day 4 to day 11. Results: Throughout the six cycles of chemotherapy, EPO-treated patients maintained stable values of hemoglobin, whereas control patients developed a progressive anemia. At the end of chemotherapy, the mean (± SD) hemoglobin decrease in the control group was 3.05 g/dL (± 1.0; 95% confidence interval [CI], 2.6 to 3.5), whereas in the EPO group it was 0.8 (± 1.4; 95% CI, 0.3 to 1.4). Clinically significant anemia (hemoglobin ≤ 10 g/dL) occurred in 16 patients (52%; 95% CI, 33 to 69) in the control arm and in no patient (0%; 95% CI, 0 to 14) in the EPO arm (P = .00001). Conclusion: EPO prevents anemia in patients undergoing chemotherapy. Further trials are required to identify subsets of patients in which the preventive use of this drug could be cost-effective.

UR - http://www.scopus.com/inward/record.url?scp=17144459940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144459940&partnerID=8YFLogxK

M3 - Article

C2 - 9215845

AN - SCOPUS:17144459940

VL - 15

SP - 2715

EP - 2721

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -